Loading

Patrick Daly

Patrick Daly is a contributing writer for GU Oncology Now. He is an assistant editor for DocWire News with several years of experience in producing multimedia content for B2B and B2C audiences in the financial and health care industries.

Articles by Patrick Daly

Patrick Daly

ESMO 2022 | September 14, 2022

Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.

Patrick Daly

ESMO 2022 | September 14, 2022

A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.

Patrick Daly

ESMO 2022 | September 14, 2022

Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.

Patrick Daly

ESMO 2022 | September 14, 2022

PRESTO trial results show adding APA and AAP to ADT improved biochemical PFS in patients with relapsed prostate cancer.

Patrick Daly

ESMO 2022 | September 12, 2022

177Lu-PSMA-RLT showed efficacy and safety consistent with published evidence in cohort of very old patients with mCRPC.

Patrick Daly

ESMO 2022 | September 12, 2022

Karim Fizazi discussed preliminary findings on ODM-208, a first-in-class CYP11A1 inhibitor at ESMO 2022.

Patrick Daly

ESMO 2022 | September 12, 2022

Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.

Patrick Daly

ESMO 2022 | September 10, 2022

Researchers evaluated immune effects of enzalutamide in patients with metastatic castration-resistant prostate cancer on ADT.

Patrick Daly

ESMO 2022 | September 10, 2022

Pembrolizumab plus olaparib did not improve survival versus alternating from abiraterone or enzalutamide in mCRPC.

Patrick Daly

ESMO 2022 | September 10, 2022

This randomized controlled trial was part of a series of trials conducted under the RADICALS protocol.